Association between asymptomatic hyperuricaemia and metabolic syndrome in the adolescents

Česká verzia

Authors: Ivana Koborová ¹; Radana Gurecká ¹; Anna Hlavatá ²; Katarína Šebeková ¹
Authors place of work: Ústav molekulárnej biomedicíny LF UK Bratislava, Slovenská republika, prednosta doc. MUDr. Ing. RNDr. Peter Celec, PhD., MPH ¹; II. detská klinika LF UK a Nemocnica akad. L. Dérera, FNsP Bratislava, Slovenská republika, prednosta prof. MUDr. László Kovács, DrSc., MPH ²
Published in the journal: Vnitř Lék 2015; 61(1): 42-49
Category: Reviews

Prednesené v skrátenej forme na 7. slovenskej konferencii detskej nefrológie s medzinárodnou účasťou, 5. – 6. júna 2014 v Košiciach, Slovenská republika.

Summary

In humans, uric acid represents a biologically active end-product of purine nucleotides. Several studies in children and adolescents documented an association between hyperuricaemia and the components metabolic syndrome. High intake of fructose-sweetened beverages might increase uricaemia, since fructose is the only saccharide which metabolism results in the formation of uric acid. Current knowledge does not allow distinguishing whether hyperuricaemia is causally related to the components of metabolic syndrome, or rather represents a marker of an enhanced risk, and poor outcome. No guidelines exist whether or not to treat asymptomatic hyperuricaemia in the adolescents. Randomized controlled prospective clinical studies are needed to elucidate whether uric acid-lowering management would beneficially affect the prevalence of metabolic syndrome, and the incidence of cardiovascular disease.

Key words:
adolescents fructose – insulin resistance– metabolic syndrome – obesity – uric acid

Zdroje

1. Watanabe S, Kang DH, Feng LL et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40(3): 355–360.

2. Johnson RJ, Titte S, Cade JR et al. Uric acid, evolution and primitive cultures. Semin Nephrol 2005; 25(1): 3–8.

3. Orowan E. The origin of man. Nature 1955; 175(4459): 683–684.

4. Ames BN, Cathcart R, Schwiers E et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981; 78(11): 6858–6862.

5. Waring WS, McKnight JA, Webb DJ et al. Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers. Diabetes 2006; 55(11): 3127–3132.

6. Johnson RJ, Kang DH, Feig D et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41(6): 1183–1190.

7. Nakanishi N, Okamoto M, Yoshida H et al. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol 2003; 18(6): 523–530.

8. Wheeler JG, Juzwishin KDM, Eiriksdottir G et al. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med 2005; 2(3): e76. Dostupné z DOI: <http://doi 10.1371/journal.pmed.0020076>.

9. Neogi T. Asymptomatic hyperuricemia: perhaps not so benign? J Rheumatol 2008; 35(5): 734–737.

10. Johnson RJ, Nakagawa T, Sanchez-Lozada LG et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes 2013; 62(10): 3307–3315.

11. van den Berghe G, Bronfman M, Vanneste R et al. The mechanism of adenosine triphosphate depletion in the liver after a load of fructose. A kinetic study of liver adenylate deaminase. Biochem J 1977; 162(3): 601–609.

12. Cox CL, Stanhope KL, Schwarz JM et al. Consumption of fructose-sweetened beverages for 10 weeks reduces net fat oxidation and energy expenditure in overweight/obese men and women. Eur J Clin Nutr 2012; 66(2): 201–208.

13. Cox CL, Stanhope KL, Schwarz JM et al. Circulating Concentrations of Monocyte Chemoattractant Protein-1, Plasminogen Activator Inhibitor-1, and Soluble Leukocyte Adhesion Molecule-1 in Overweight/Obese Men and Women Consuming Fructose-or Glucose-Sweetened Beverages for 10 Weeks. J Clin Endocrinol Metab 2011; 96(12): E2034-E2038.

14. Stanhope KL, Havel PJ. Fructose Consumption: Considerations for Future Research on Its Effects on Adipose Distribution, Lipid Metabolism, and Insulin Sensitivity in Humans. J Nutr 2009; 139(6): S1236-S1241.

15. Perez-Pozo SE, Schold J, Nakagawa T et al. Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. Int J Obes (Lond) 2010; 34(3): 454–461.

16. Teff KL, Elliott SS, Tschop M et al. Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. J Clin Endocrinol Metab 2004; 89(6): 2963–2972.

17. Lane MD, Cha SH. Effect of glucose and fructose on food intake via malonyl-CoA signaling in the brain. Biochem Biophys Res Commun 2009; 382(1): 1–5.

18. Kneepkens CM, Vonk RJ, Fernandes J. Incomplete intestinal absorption of fructose. Arch Dis Child 1984; 59(8): 735–738.

19. Ravich WJ, Bayless TM, Thomas M. Fructose: incomplete intestinal absorption in humans. Gastroenterology 1983; 84(1): 26–29.

20. Masseoud D, Rott K, Liu-Bryan R et al. Overview of hyperuricaemia and gout. Curr Pharm Des 2005; 11(32): 4117–4124.

21. Reyes AJ. The increase in serum uric acid concentration caused by diuretics might be beneficial in heart failure. Eur J Heart Fail 2005; 7: 461–467.

22. Koettgen A, Albrecht E, Teumer A et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet 2013; 45(2): 145–154.

23. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486–2497.

24. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16(5): 442–443.

25. Alberti K, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23(5): 469–480.

26. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. World Health Organization: Geneva 1999. Dostupné z WWW: <http://whqlibdoc.who.int/hq/1999/who_ncd_ncs_99.2.pdf>.

27. Vitariusova E, Kostalova L, Pribilincova Z et al. Problems of metabolic syndrome diagnostics in children. Endocr Regul 2010; 44(3): 115–120.

28. Kumstát M, Hejmalová M, Hrazdira L et al. Problematika výživových zvyklostí II. Masarykova Univerzita: Brno 2013. ISBN 978–80–210–6334–1. ISBN 978–80–210–6335–8 (online : iOS). ISBN 978–80–210–6336–5 (online : Android). ISBN 978–80–210–6333–4 (brož. vaz.). Dostupné z WWW: <http://DOI: 10.5817/CZ.MUNI.M210–6334–2013>.

29. Zimmet P, Alberti KG, Kaufman F et al. The metabolic syndrome in children and adolescents – an IDF consensus report. Pediatr Diabetes 2007; 8(5): 299–306.

30. Kurtoglu S, Akin L, Kendirci M et al. The absence of insulin resistance in metabolic syndrome definition leads to underdiagnosing of metabolic risk in obese patients. Eur J Pediatr 2012; 171(9): 1331–1337.

31. Mazzali M, Hughes J, Kim YG et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38(5): 1101–1106.

32. Sanchez-Lozada LG, Soto V, Tapia E et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol 2008; 295(4): F1134-F1141.

33. Bellomo G. Uric acid and chronic kidney disease: A time to act? World J Nephrol 2013; 2(2): 17–25.

34. Khosla UM, Zharikov S, Finch JL et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67(5): 1739–1742.

35. Mazzali M, Kanellis J, Han L et al. Hyperuricemia induces a primary renal arteriolapathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002; 282(6): F991-F997.

36. Nakagawa T, Mazzali M, Kang DH et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 2003; 23(1): 2–7.

37. Kang DH, Park SK, Lee IK et al. Uric acid-induced C-reactive protein expression: Implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16(12): 3553–3562.

38. Kanellis J, Watanabe S, Li JH et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003; 41(6): 1287–1293.

39. Lanaspa MA, Sanchez-Lozada LG, Cicerchi C et al. Uric Acid Stimulates Fructokinase and Accelerates Fructose Metabolism in the Development of Fatty Liver. PLoS One 2012; 7(10): e47948. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0047948>.

40. Ryu ES, Kim MJ, Shin HS et al. Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Renal Physiol 2013; 304(5): F471-F480.

41. Puig JG, Ruilope LM. Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens 1999; 17(7): 869–872.

42. Alper AB, Chen W, Yau L et al. Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension 2005; 45(1): 34–38.

43. Gruskin AB. The adolescent with essential hypertension. Am J Kidney Dis 1985; 6(2): 86–90.

44. Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension 2003; 42(3): 247–252.

45. Špinar J, Vítovec J, Pařenica J. Hypertenze a hyperurikemie. Vnitř Lék 2005; 51(1): 82–86.

46. Koborová I, Kollárová R, Podracká Ľ et al. Asymptomatická hyperurikémia pri hypertenzii u mladistvých. Čes Slov Pediatr 2014; 69(3): 168–177.

47. Fruehwald-Schultes B, Peters A, Kern W et al. Serum leptin is associated with serum uric acid concentrations in humans. Metabolism 1999; 48(6): 677–680.

48. Matsuura F, Yamashita S, Nakamura T et al. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: Visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism 1998; 47(8): 929–933.

49. de Oliveira EP, Moreto F, de Arruda Silveira LV et al. Dietary, anthropometric, and biochemical determinants of uric acid in free-living adults. Nutr J 2013; 12: 11. Dostupné z DOI: <http://doi: 10.1186/1475–2891–12–11>.

50. Simental-Mendia LE, Rodriguez-Moran M, Guerrero-Romero F. Failure of beta-cell function to compensate lack of insulin action in hyperuricemic subjects. Diabetes Metab Res Rev 2009; 25(6): 535–541.

51. Ter Maaten JC, Voorburg A, Heine RJ et al. Renal handling of urate and sodium during acute physiological hyperinsulinaemia in healthy subjects. Clin Sci (Lond) 1997; 92(1): 51–58.

52. Cappuccio FP, Strazzullo P, Farinaro E et al. Uric acid metabolism and tubular sodium handling – results from a population-based study. JAMA 1993; 270(3): 354–359.

53. Hofmann SM, Tschoep MH. Dietary sugars: a fat difference. J Clin Invest 2009; 119(5): 1089–1092.

54. Tsouli SG, Liberopoulos EN, Mikhailidis DP et al. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006; 55(10): 1293–1301.

55. Mangge H, Pilz S, Haj-Yahya S et al. Uric acid indicates a high cardiovascular risk profile but is not closely associated with insulin resistance in obese adolescents. Diabetes Care 2008; 31(4): e21. Dostupné z DOI: <http://doi: 10.2337/dc07–2411>.

56. Tang L, Kubota M, Nagai A et al. Hyperuricemia in obese children and adolescents: the relationship with metabolic syndrome. Pediatr Rep 2010; 2(1): e12. Dostupné z DOI: <http:// doi: 10.4081/pr.2010.e12>.

57. Kytnarová J, Frühauf P, Moravcová A et al. Možnosti sonografického zjišťování množství viscerálního tuku u obézních dětí. Čas Lék Česk 2004; 143(11): 766–769.

58. Schusterova I, Leenen FHH, Jurko A et al. Epicardial adipose tissue and cardiometabolic risk factors in overweight and obese children and adolescents. Pediatr Obes 2014; 9(1): 63–70.

59. Soletsky B, Feig DI. Uric Acid Reduction Rectifies Prehypertension in Obese Adolescents. Hypertension 2012; 60(5): 1148–1156.

60. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension – A randomized trial. JAMA 2008; 300(8): 924–932.

61. Feig DI. The Role of Uric Acid in the Pathogenesis of Hypertension in the Young. J Clin Hypertens (Greenwich) 2012; 14(6): 346–352.

62. Krzystek-Korpacka M, Patryn E, Kustrzeba-Wojcicka I et al. The effect of a one-year weight reduction program on serum uric acid in overweight/obese children and adolescents. Clin Chem Lab Med 2011; 49(5): 915–921.

63. Cole TJ, Bellizzi MC, Flegal KM et al. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000; 320 (7244): 1240–1243.

64. Park HS, Sim SJ, Park JY. Effect of weight reduction on metabolic syndrome in Korean obese patients. J Korean Med Sci 2004; 19(2): 202–208.

65. Tetradze L, Virsaladze D, Javashvili L et al. Relation of serum uric acid levels with basic metabolic parameters in patients with metabolic syndrome during insulin-sensitizing therapy. Georgian Med News 2007; 151: 44–47.

66. Barskova VG, Eliseev MS, Kudaeva FM et al. Effect of metformin on the clinical course of gout and insulin resistance. Klin Med (Mosk) 2009; 87(7): 41–46.

67. Uysal Y, Wolters B, Knop C et al. Components of the metabolic syndrome are negative predictors of weight loss in obese children with lifestyle intervention. Clin Nutrition 2014; 33(4): 620–625.

68. Válek J, Vlasáková Z. Metabolický syndrom, dĕdicnost, způsob detekce a klinický význam. Vnitř Lék 1997; 43(9): 566–573.

69. Molnar D, Decsi T, Koletzko B. Reduced antioxidant status in obese children with multimetabolic syndrome. Int J Obes Relat Metab Disord 2004; 28(10): 1197–1202.

70. Ford ES, Li CY, Cook S et al. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 2007; 115(19): 2526–2532.

71. Weghuber D, Zelzer S, Stelzer I et al. High risk vs. “metabolically healthy” phenotype in juvenile obesity – neck subcutaneous adipose tissue and serum uric acid are clinically relevant. Exp Clin Endocrinol Diabetes 2013; 121(7): 384–390.

72. Mangge H, Zelzer S, Puerstner P et al. Uric Acid Best Predicts Metabolically Unhealthy Obesity With Increased Cardiovascular Risk in Youth and Adults. Obesity (Silver Spring) 2013; 21(1): E71-E77. Dostupné z DOI: <http:// doi: 10.1002/oby.20061>.

73. Hongo M, Hidaka H, Sakaguchi S et al. Association Between Serum Uric Acid Levels and Cardiometabolic Risk Factors Among Japanese Junior High School Students. Circ J 2010; 74(8): 1570–1577.

74. Wang JY, Chen YL, Hsu CH et al. Predictive Value of Serum Uric Acid Levels for the Diagnosis of Metabolic Syndrome in Adolescents. J Pediatr 2012; 161(4): 753–756.

75. Wiik BP, Larstorp ACK, Hoieggen A et al. Serum Uric Acid Is Associated With New-Onset Diabetes in Hypertensive Patients With Left Ventricular Hypertrophy: The LIFE Study. Am J Hypertens 2010; 23(8): 845–851.

76. Lv Q, Meng XF, He FF et al. High Serum Uric Acid and Increased Risk of Type 2 Diabetes: A Systemic Review and Meta-Analysis of Prospective Cohort Studies. PLoS One 2013; 8(2): e56864. Dostupné z DOI: <http://doi: 10.1371/journal.pone.0056864>.

77. Madero M, Arriaga JC, Jalal D et al. The effect of two energy-restricted diets, a low-fructose diet versus a moderate natural fructose diet, on weight loss and metabolic syndrome parameters: a randomized controlled trial. Metabolism 2011; 60(11): 1551–1559.

78. Dincer HE, Dincer AP, Levinson DJ. Asymptomatic hyperuricemia: to treat or not to treat. Cleve Clin J Med 2002; 69(8): 594, 597, 600–602 passim.